What the new Portugal guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Dosing
Page 10 of 31 of this archive, newest first.
What SELECT tells us about maintenance, and what it does not
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
The ceiling is a tolerability finding, not an efficacy one
Higher doses of these molecules have been studied. In general they produced modest additional efficacy and disproportionate additional symptom burden, which is why the…
Dual, triple, co-formulated: a taxonomy the coverage keeps collapsing
Head-to-head data exists for some of these comparisons and not for others. This piece says which.
Target dose, effective dose, and the distance between them
The dose-response curve in this class flattens near its top. That has direct consequences for whether the final rung is worth climbing.
Not everybody regains at the same rate, and nobody knows why
The variance around the mean regain trajectory is large and unexplained, exactly as it is for the weight loss.
Why the fifth week of a mazdutide dose feels different from the first
The exposure curve explains the timing of both the benefit and the side effects. It is almost never shown to the person injecting.
Vagal afferents, the area postrema, and the anatomy of nausea
Receptor expression maps explain the effect profile better than any dose-response curve.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Ireland pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
Severity grading, and the gap between a grade and an experience
Severity in these tables is graded by interference with activity, not by how unpleasant the experience was. Those are different measurements.
Forty-four per cent: reading the nausea figure properly
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
Background rates, and why they matter for attribution
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Escalating past the approved maximum, examined honestly
Where the curve flattens, what flattens with it, and what does not.
Gallstones during rapid weight loss: drug, or weight loss?
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
The limits of mechanism: why receptor data will not tell you who responds
A catalogue of open questions, with an assessment of how likely each is to be resolved.
The intramuscular injection nobody intended
Skin thickness at the standard injection sites is approximately two millimetres in adults and varies remarkably little with body mass. That single finding is why short…
Continued treatment against continued placebo: the comparison that settled it
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
The shortage years, and what they taught about interruption
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.